TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34397104

Group type: EXPERIMENTAL
Intervention: 0.1% PVP-I nasal irrigation
Number of subjects: 55

Group type: COMPARATOR
Intervention: Normal saline irrigation (Control)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Comparison between PVP-I and Normal saline
Number of subjects: 55
Study: 32196748

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (∼10g/day increase)
Number of subjects: 0
Study: 36050816

Group type: EXPERIMENTAL
Intervention: Preoperative antibiotics
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 34704716

Group type: EXPERIMENTAL
Intervention: 3-needle technique (TN group [n = 25])
Number of subjects: 50

Group type: COMPARATOR
Intervention: single-needle technique (SN group [n = 25])
Number of subjects: 50
Study: 34871640

Group type: EXPERIMENTAL
Intervention: eHealth program targeting depression
Number of subjects: 125
Study: 36127627

Group type: EXPERIMENTAL
Intervention: Depression care intervention
Number of subjects: 391
Study: 34647190

Group type: EXPERIMENTAL
Intervention: ELA + DCB
Number of subjects: 79

Group type: COMPARATOR
Intervention: DCB
Number of subjects: 79
Study: 33258781

Group type: EXPERIMENTAL
Intervention: Active telehealth (n=471)
Number of subjects: 1373

Group type: COMPARATOR
Intervention: Usual care (n=293)
Number of subjects: 1373
Study: 34767999

Group type: EXPERIMENTAL
Intervention: HDM Sublingual Immunotherapy (SLIT) for 18 months
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo for 18 months
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: HDM SLIT
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 34279606

Group type: EXPERIMENTAL
Intervention: Physiology-guided incremental optimization strategy (PIOS)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control group (blinded coronary physiology assessment)
Number of subjects: 260
Study: 32032923

Group type: EXPERIMENTAL
Intervention: Spironolactone (2‐4 mg q 24 h) and benazepril (0.25‐0.5 mg q 24 h)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Spironolactone and benazepril
Number of subjects: 184
Study: 36057612

Group type: EXPERIMENTAL
Intervention: HEALTHY‐MIND©
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DEEPSEN©
Number of subjects: 60
Study: 36401916

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality sessions (three sessions)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 19
Study: 33784428

Group type: EXPERIMENTAL
Intervention: Height increase (1 SD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 0

Group type: COMPARATOR
Intervention: WHR, HC, WC (adjusted for BMI)
Number of subjects: 0
Study: 35939350

Group type: EXPERIMENTAL
Intervention: Tidal volume of 6 ml/kg
Number of subjects: 2860

Group type: COMPARATOR
Intervention: Tidal volume of 10 ml/kg
Number of subjects: 2860

Group type: EXPERIMENTAL
Intervention: PEEP of 5 cm H2O
Number of subjects: 2860

Group type: COMPARATOR
Intervention: PEEP of 8 cm H2O
Number of subjects: 2860
Study: 33687101

Group type: EXPERIMENTAL
Intervention: Individual resiliency training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family psychoeducation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supported education and employment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structural assessment for medication
Number of subjects: 0
Study: 35280426

Group type: EXPERIMENTAL
Intervention: Intermittent dose apatinib (500 mg/d for 5 days, then 2 days off) plus docetaxel (60 mg/m2 q3w)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Continuous dose apatinib (500 mg daily) plus docetaxel (60 mg/m2 q3w)
Number of subjects: 76
Study: 32409106

Group type: EXPERIMENTAL
Intervention: Daratumumab
Number of subjects: 1798

Group type: COMPARATOR
Intervention: Comparator
Number of subjects: 1798
Study: 35639493

Group type: EXPERIMENTAL
Intervention: EMPOWER intervention (digital smartphone app for monitoring well-being)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: EMPOWER intervention
Number of subjects: 86
Study: 33200390

Group type: EXPERIMENTAL
Intervention: 1% tropicamide
Number of subjects: 83

Group type: COMPARATOR
Intervention: 1% cyclopentolate hydrochloride
Number of subjects: 83
Study: 32741788

Group type: EXPERIMENTAL
Intervention: Neuromuscular electric stimulation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (conventional physical therapy only)
Number of subjects: 60
Study: 35570898

Group type: EXPERIMENTAL
Intervention: 6-week tailored web-based educational lifestyle program
Number of subjects: 35

Group type: COMPARATOR
Intervention: 6-week generic standard-care educational course
Number of subjects: 35
Study: 33940670

Group type: EXPERIMENTAL
Intervention: SnF2 dentifrice A
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: SnF2 dentifrice B
Number of subjects: 161

Group type: COMPARATOR
Intervention: Zn/Arg dentifrice
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Both SnF2 dentifrices
Number of subjects: 161

Group type: COMPARATOR
Intervention: Negative control dentifrice
Number of subjects: 161
Study: 34274622

Group type: EXPERIMENTAL
Intervention: Arts therapies (including story-making, story-telling, drawings, puppetry, songwriting, and empowerment activities)
Number of subjects: 62
Study: 32991336

Group type: EXPERIMENTAL
Intervention: Self-reported living with HIV and on ART
Number of subjects: 5662

Group type: EXPERIMENTAL
Intervention: Self-reported living with HIV and not on treatment
Number of subjects: 5662

Group type: EXPERIMENTAL
Intervention: Self-identifying PLHIV with internalized stigma
Number of subjects: 5662

Group type: EXPERIMENTAL
Intervention: Self-identifying PLHIV without internalized stigma
Number of subjects: 5662
Study: 32691984

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Galantamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivastigmine
Number of subjects: 0
Study: 35522990

Group type: EXPERIMENTAL
Intervention: Cognitively engaging physical activity (CPA; storytelling, cognitive activities, and motor tasks, n = 55)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Cognition (storytelling and cognitive activities without motor tasks, n = 48)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control (traditional storytelling, n = 41)
Number of subjects: 144
Study: 34965588

Group type: EXPERIMENTAL
Intervention: Maternal height
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Paternal height
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Maternal glucose, insulin resistance, and fetal C-peptide
Number of subjects: 556
Study: 35435818

Group type: EXPERIMENTAL
Intervention: Myomectomy
Number of subjects: 254

Group type: COMPARATOR
Intervention: Uterine artery embolisation
Number of subjects: 254
Study: 33596937

Group type: EXPERIMENTAL
Intervention: PPIUD intervention
Number of subjects: 96
Study: 36239883

Group type: EXPERIMENTAL
Intervention: Trifluridine‐tipiracil plus bevacizumab
Number of subjects: 31

Group type: COMPARATOR
Intervention: Trifluridine‐tipiracil monotherapy
Number of subjects: 31
Study: 32051344

Group type: EXPERIMENTAL
Intervention: Kisspeptin
Number of subjects: 0
Study: 35681960

Group type: EXPERIMENTAL
Intervention: Public health nurses
Number of subjects: 8975

Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 8975

Group type: EXPERIMENTAL
Intervention: Public health nurses (after adjustment)
Number of subjects: 8975

Group type: EXPERIMENTAL
Intervention: Nurses (after adjustment)
Number of subjects: 8975
Study: 33245847

Group type: EXPERIMENTAL
Intervention: Intravenous belimumab 10 mg/kg every 4 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 53
Study: 36273149

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (RYGB)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Laparoscopic one-anastomosis gastric bypass (OAGB)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 220

Group type: COMPARATOR
Intervention: OAGB
Number of subjects: 220
Study: 33572416

Group type: EXPERIMENTAL
Intervention: Matured Peruíbe Black Mud (PBM)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Sterilized Peruíbe Black Mud (PBM)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 41
Study: 35669048

Group type: EXPERIMENTAL
Intervention: Beyond Burger (PBMA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lamb
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pasture
Number of subjects: 30

Group type: COMPARATOR
Intervention: Grain
Number of subjects: 30
Study: 34975168

Group type: EXPERIMENTAL
Intervention: Herbal remedy for treatment of canine osteoarthritis pain
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 33332813

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Systemic medications (including cholinesterase inhibitor, ACE inhibitors, calcium channel blockers, beta‐blockers, diuretics, aspirin, steroids, statins, hormone replacement therapy, antacids, and drugs targeting G protein‐coupled receptors)
Number of subjects: 1011
Study: 35543459

Group type: EXPERIMENTAL
Intervention: Hand expressing and breast massage within the 1st hr of birth
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard care, hand expressing within 6 hr of birth
Number of subjects: 31
Study: 34186487

Group type: EXPERIMENTAL
Intervention: Maternal vaginal microbes (CS-seeded)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sterile water (CS-placebo)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Vaginally-born neonates (VB)
Number of subjects: 25
Study: 35912303

Group type: EXPERIMENTAL
Intervention: Preconception picture‐based nutrition education and counselling along with iron-folic acid supplementation (IFAS)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Preconception iron-folic acid supplementation (IFAS) only
Number of subjects: 244
Study: 32688368

Group type: EXPERIMENTAL
Intervention: Nutritional supplements (various types) for 12 weeks
Number of subjects: 279
Study: 32861377

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Sham preconditioning
Number of subjects: 162
Study: 36272309

Group type: EXPERIMENTAL
Intervention: Epilepsy self-management (ESM) intervention
Number of subjects: 627

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 627
Study: 33001400

Group type: EXPERIMENTAL
Intervention: Mathematical model for predicting intracranial pressure (ICP) based on phase‐contrast cine MRI (PC‐MRI) parameters.
Number of subjects: 138

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 138
Study: 36305992

Group type: EXPERIMENTAL
Intervention: Continuous infusional 5-FU for 7 days starting within 24 hours after curative resection (arm A)
Number of subjects: 855

Group type: COMPARATOR
Intervention: No perioperative 5-FU (arm B)
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Continuous infusional 5-FU for 7 days (arm A)
Number of subjects: 855
Study: 32319465

Group type: EXPERIMENTAL
Intervention: Juice enriched with highly polymerized inulin (12 g per 300 mL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 35391574

Group type: EXPERIMENTAL
Intervention: High Intensity (HI) exercise
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Low-to-Moderate Intensity (LMI) exercise
Number of subjects: 577

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 577
Study: 34235773

Group type: EXPERIMENTAL
Intervention: Pre-COVID-19 condition (retrospective assessment)
Number of subjects: 6578

Group type: COMPARATOR
Intervention: Current condition (during the pandemic assessment)
Number of subjects: 6578

Group type: EXPERIMENTAL
Intervention: Cyber bullying
Number of subjects: 6578

Group type: COMPARATOR
Intervention: East Asian Canadian students vs. White students
Number of subjects: 6578

Group type: COMPARATOR
Intervention: Gender comparison
Number of subjects: 6578

Group type: COMPARATOR
Intervention: Elementary vs. Secondary students
Number of subjects: 6578

Group type: COMPARATOR
Intervention: Gender diverse and LGBTQ+ students
Number of subjects: 6578
Study: 33234155

Group type: EXPERIMENTAL
Intervention: Standardized LTC‐ED care and referral pathway with targeted INTERACT® tools
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Post-implementation qualitative assessment of the pathway
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Comparative cost-analysis from the perspective of publicly funded health care
Number of subjects: 38
Study: 35320494

Group type: EXPERIMENTAL
Intervention: RECOVEREEZ FORTE™ (500 mg thrice daily for 10 days)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (standard of care and oral Prednisolone in tapered dosage)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: RECOVEREEZ FORTE™
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: IFM RT-PCR test
Number of subjects: 64
Study: 34132351

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (GLN)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Negative control (GRY)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Positive control (GNY)
Number of subjects: 16
Study: 32780739

Group type: EXPERIMENTAL
Intervention: Continuous exercise with mask (CE‐ARM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Continuous exercise without mask (CE)
Number of subjects: 18
Study: 35245946

Group type: EXPERIMENTAL
Intervention: Adjunctive membrane sweeping with Foley catheter
Number of subjects: 63

Group type: COMPARATOR
Intervention: Foley catheter (no membrane sweeping)
Number of subjects: 63
Study: 33707267

Group type: EXPERIMENTAL
Intervention: Pleuran oral suspension
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 33347725

Group type: EXPERIMENTAL
Intervention: Responsive complementary feeding and play group (RCF&P group)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Complementary feeding group (CF group)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 600
Study: 35574029

Group type: EXPERIMENTAL
Intervention: Time-Restricted Feeding (TRF)
Number of subjects: 12
Study: 33635238

Group type: EXPERIMENTAL
Intervention: Histidine-Tryptophan-Ketoglutarate (HTK) solution
Number of subjects: 320

Group type: COMPARATOR
Intervention: Blood cardioplegia
Number of subjects: 320
Study: 35327782

Group type: EXPERIMENTAL
Intervention: MTA apical plugs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Biodentine apical plugs
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (MTA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (Biodentine)
Number of subjects: 24
Study: 32591004

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) - loading dose of 1 μg/kg over 10 min followed by continuous infusion of 0.5 μg/kg/h until the end of surgery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (0.9% saline) - equal volume loading dose followed by equal volume continuous infusion until the end of surgery
Number of subjects: 200
Study: 35363122

Group type: EXPERIMENTAL
Intervention: 30‐min Stroop task
Number of subjects: 0

Group type: COMPARATOR
Intervention: 30‐min documentary program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjective ratings of mental fatigue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual analog scale
Number of subjects: 0
Study: 32521538

Group type: EXPERIMENTAL
Intervention: Colonic SCFA delivery (10 g and 20 g of arabinoxylan oligosaccharides)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 36379436

Group type: EXPERIMENTAL
Intervention: Strong Together serious game
Number of subjects: 336

Group type: COMPARATOR
Intervention: Enhanced care as usual
Number of subjects: 336
Study: 32595137

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention (10 hours/week for 6 months) including medication reviews, prescribing advice, clinical audits, and education.
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention for older adults (aged ≥65 years) with polypharmacy.
Number of subjects: 786
Study: 34825613

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 96
Study: 32062048

Group type: EXPERIMENTAL
Intervention: 8 weeks of once-weekly rifapentine plus isoniazid (group A)
Number of subjects: 2618

Group type: EXPERIMENTAL
Intervention: 6 weeks of twice-weekly rifapentine plus isoniazid (group B)
Number of subjects: 2618

Group type: COMPARATOR
Intervention: Untreated controls (group C)
Number of subjects: 2618

Group type: EXPERIMENTAL
Intervention: Treated participants with higher baseline IFN-γ levels
Number of subjects: 2618

Group type: COMPARATOR
Intervention: Untreated controls with higher baseline IFN-γ levels
Number of subjects: 2618
Study: 34455455

Group type: EXPERIMENTAL
Intervention: New screwed Amplatz sheath (Group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional Amplatz sheath (Group A)
Number of subjects: 100
Study: 34971614

Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (CVR) releasing NES and E2
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Out-of-range NES concentrations
Number of subjects: 443
Study: 32127255

Group type: EXPERIMENTAL
Intervention: Active‐Start intervention (daily before-school physical activity program for 8 weeks)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Active‐Start intervention
Number of subjects: 170
Study: 35083341

Group type: EXPERIMENTAL
Intervention: Probiotic mixture (Ligilactobacillus salivarius LS01 1 × 10^9 live cells and Bifidobacterium breve B632 1 × 10^9 live cells) taken twice daily for eight weeks and then once daily for another eight weeks
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Probiotic mixture (Ligilactobacillus salivarius LS01 and Bifidobacterium breve)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study: 33743670

Group type: EXPERIMENTAL
Intervention: Task-oriented exercises
Number of subjects: 70
Study: 32033579

Group type: EXPERIMENTAL
Intervention: Continuation of antipsychotic medication until at least 1 year after remission (original dose allowing a maximum reduction of 25%, or another antipsychotic drug in similar dose range)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Gradual dose reduction till eventual discontinuation of antipsychotics according to a tapering schedule
Number of subjects: 512
Study: 32030432

Group type: EXPERIMENTAL
Intervention: Standard care + nature-based rehabilitation
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 101
Study: 34751427

Group type: EXPERIMENTAL
Intervention: Radiofrequency thermocoagulation at 90°C for 50 seconds
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Radiofrequency thermocoagulation at 85°C for 60 seconds
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Radiofrequency thermocoagulation at 70°C for 90 seconds
Number of subjects: 96

Group type: COMPARATOR
Intervention: All groups (90°C, 85°C, 70°C)
Number of subjects: 96
Study: 34484368

Group type: EXPERIMENTAL
Intervention: Sedation with midazolam with/out pethidine
Number of subjects: 275

Group type: COMPARATOR
Intervention: Uns sedation
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Pain during rectal examination
Number of subjects: 275
Study: 35759555

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg/Acetaminophen 1000 mg
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 33829946

Group type: EXPERIMENTAL
Intervention: Slow chest compression (SCC) after exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (rest after exercise)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Slow chest compression (SCC) responders
Number of subjects: 40
Study: 32796574

Group type: EXPERIMENTAL
Intervention: Optimising the Health Extension Program intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: N/A (Control group)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: N/A (Intervention activities)
Number of subjects: 52
Study: 34402887

Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study: 34493820

Group type: EXPERIMENTAL
Intervention: Molecular-matched treatment
Number of subjects: 87

Group type: COMPARATOR
Intervention: Best investigator's choice (standard therapy)
Number of subjects: 87
Study: 34501940

Group type: EXPERIMENTAL
Intervention: TENS (transcutaneous electrical stimulation)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 33486749

Group type: EXPERIMENTAL
Intervention: Metrx approach (minimally invasive transmuscular approach using a tubular retractor system)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Conventional microsurgical approach (CM)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Metrx approach
Number of subjects: 227
Study: 32762446

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional 12-month DAPT
Number of subjects: 0
Study: 35311719

Group type: EXPERIMENTAL
Intervention: Functional trunk training (3 days/week for 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Trunk stabilization and balance exercises (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Functional trunk training
Number of subjects: 20
Study: 32911138

Group type: EXPERIMENTAL
Intervention: Corticosteroid
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 35698215

Group type: EXPERIMENTAL
Intervention: Anthroposophic supportive treatment (AST)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control (no anthroposophic base medication)
Number of subjects: 288

Group type: COMPARATOR
Intervention: AST and Control
Number of subjects: 288
Study: 33509035

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 44

Group type: COMPARATOR
Intervention: Education only (control group)
Number of subjects: 44
Study: 34998436

Group type: EXPERIMENTAL
Intervention: Receiving study results (summary of study results via letter)
Number of subjects: 304